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OBJECTIVES: The Diabetes Mellitus Model can be used to sim-
ulate the cumulative incidences of short and long-term diabetes
complications over 10 years in patients with type-2 diabetes. In
this study, the DMM was used to investigate the inﬂuence of ‘rate
of patients treated to target A1c’ (responder rate) and ‘delay in
starting intensiﬁed therapy’ on the cumulative incidence of long-
term complications in patients with type-2 diabetes.
METHODS: A population of virtual patients was simulated
based on published demographic and physiological baseline
values at the start of the simulation (mean baseline A1c 9%), on
which two analyses were carried out. In the ﬁrst analysis, the
responder rate was varied in 20% steps from 0–100% and 5
cohorts were simulated. The second analysis comprised 10 sim-
ulated cohorts evaluating the ‘delay in starting intensiﬁed
therapy, which was varied in 1-year steps between 1 and 10
years. For all simulated patients, HbA1c increased by 0.1% per
year. RESULTS: Both parameters have a large impact on the
cumulative incidence of long-term complications in patients with
type-2 diabetes, especially on macrovascular complications.
After 10 years, the simulated cohort of 100% responders showed
a 43% and 24% risk reduction for micro and macro-vascular
complications compared to the cohort of 0% responders.
Patients who started intensiﬁed therapy (target A1c < 6.5%) in
year 1 of the simulation showed 77% and 33% risk reduction
for micro and macro-vascular complications compared to
patients who started intensiﬁed therapy in the tenth. A 3-year
delay in initiation of intensiﬁed therapy gave a 20% risk reduc-
tion for microvascular complications versus initiation in year 10.
CONCLUSIONS: This analysis highlights the importance of
responder rate and the early initiation of intensiﬁed glycaemic
control therapy in patients with type 2-diabetes with respect to
long-term clinical outcomes.
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OBJECTIVES: The EAGLE (Economic Assessment of Glycemic
Control and Longterm Effects) model was developed to simulate
long-term effects of diabetes therapies on diabetes-related com-
plications and costs. METHODS: Based on a systematic review
of published data for type-1 and type-2 diabetes; the EAGLE
model is a stand-alone computer simulation program providing
micro-simulations of virtual patient cohorts over n years in 
1-year cycles with a maximum of 1000 iterations. Subsequent
health economic (HE) calculations are constructed from the sim-
ulation results. For internal validation the model event rates were
compared with rates of study data used to build the model.
Respective deviations with conﬁdence intervals were calculated.
RESULTS: Results from DCCT, UKPDS, and WESDR studies
were used for model calculations. Complications include micro-
and macrovascular events (e.g. neuroathy, end stage renal
disease, cardiovascular complications, stroke etc) and death, and
are calculated over time as cumulative incidence. Risk equations
for the probability of complications are based on regression
analysis using linear, exponential, as well as quadratic regression
formulae. Risk equations for probability of events include demo-
graphic (e.g. age, gender, duration of diabetes since diagnosis,
type of diabetes) and physiological parameters (e.g. A1c, systolic
blood pressure, triglycerides, HDL, LDL, albumin excretion
rate). The course of A1c over time is simulated in relation to the
treatment regimen. Country speciﬁc costs for diabetes treatments
and complications can be assigned. HE calculations include cost
of complications, cost of illness, cost-effectiveness, cost-utility
and cost consequence analysis. Output data provide incidence
per year, cumulative incidence after n years, all demographic and
physiological parameters, and results of the health economic
analyses. Internal validation demonstrated a deviation of less
then 25% from original study data for all simulated events.
CONCLUSIONS: The EAGLE model is a valid tool for the
analysis of long-term effects of diabetes treatment and related
costs.
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OBJECTIVES: The aim of this analysis was to evaluate the link
between visual impairment and diminished activity of daily
living. METHODS: A national survey (1999) was conducted on
a random, stratiﬁed sample of 356,208 French persons living in
the community. A subset of 21,760 subjects was selected at
random for further research and 16,945 were interviewed. Two
years later (2001) the same subjects were interviewed again.
Three groups were identiﬁed, based upon subject interviews
(blind, low vision (LV) and no visual problem (NVP)). Activity
of daily living (ADL) was measured by the Katz index. Loss of
ADL was deﬁned as a decrease of at least one Katz level. A
weighted stepwise logistic regression was used to determine risk
factors of ADL loss. RESULTS: ADL was documented 2 years
later for 12,310 subjects (72.65%). The 3 major reasons for
uncompleted second interviews were a move, death and refusal
to answer. The mean age at the second interview was 40.3 years,
52.3% were female and 2.06% experienced ADL loss. Age was
strongly associated with ADL loss (p < 0.001). Handicaps were
also factors: motor function (odds ratio[OR] = 2.56), speech (OR
= 2.46), brain (OR = 2.05) and visceral difﬁculties (OR = 1.81).
Visual impairment was found to be an independent factor asso-
ciated with ADL loss, i.e. LV subjects’ chance of ADL loss was
1.89 times greater while the ﬁgure for blind subjects was 5.43
(ORs adjusted on age-squared and other handicaps). CON-
CLUSIONS: For French persons living in the community, LV and
blindness are 2 independent risk factors of ADL loss within 2
years. These results suggest that preservation of visual function
would contribute to maintenance of ADL.
